Skip to Main Content

News

Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion

Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise

Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies

September 12, 2022

Press
Releases

Small Molecule Restores Mitochondrial Function in POLG Disorders

Technology Networks • April 11, 2025

Pretzel Therapeutic Reveals Novel mtDNA Deficiency Syndrome Drugs

Inside Precision Medicine • April 10, 2025

Small molecule rescues unstable mitochondrial enzyme

C&ENews • April 10, 2025

Pretzel Therapeutics narrows the therapeutic gap for PolG disease

BioWorld • April 10, 2025

Pretzel advances mitochondrial therapy with PX578 Phase 1 trial

Parkinson’s News Daily • October 8, 2025

News